Lactobacillus rhamnosus GG (ATCC 53103)

The most extensively documented probiotic strain globally, LGG demonstrates robust efficacy in pediatric acute diarrhea and respiratory tract infections.

Clinical Profile

Isolated in 1983 by Sherwood Gorbach and Barry Goldin, LGG is characterized by its strong avidity for human intestinal mucosal cells. It is supported by over 1,000 scientific publications and 300 clinical trials.

Key Efficacy Thresholds

Indication	Dosage (CFU)	Duration
Pediatric acute diarrhea	10 × 109 daily	5-7 days
AAD Prevention	10-20 × 109 daily	Concurrently with antibiotics

Formulation Considerations

LGG exhibits excellent survivability in gastric acid but is sensitive to high water activity (Aw > 0.2) in dry formats. Microencapsulation is recommended for long-term ambient stability.